Skip to content

Tuning HDAC Inhibition, Cell Uptake, and Antiproliferative Activity of Vorinostat-Derived Half-Sandwich Complexes with Phosphine Co-Ligands.

Aug 2026 · Inorganic Chemistry · Vol 65 32, pp. 18969-18984 · 0 citations · 61 references
Medicine

TL;DR

To alter the interactions between HDACs and half-sandwich organometallic HDACis, amphiphilic 1,3,5-triaza-7-phosphaadamantane (PTA) or lipophilic triphenylphosphine (PPh3) as coligands were introduced or Rh(III) derivatives exhibited promising antiproliferative and HDAC inhibitory activity compared to their chlorido precursor.

Abstract

HDAC inhibitors are used as anticancer drugs, and the Zn2+-coordinating hydroxamic acid moiety in the drug vorinostat (SAHA) plays a key role in the mode of action. The introduction of metal centers in the structures of HDAC inhibitors (HDACis) allows for additional interactions between the inhibitor and the protein. To alter the interactions between HDACs and half-sandwich organometallic HDACis, we introduced amphiphilic 1,3,5-triaza-7-phosphaadamantane (PTA) or lipophilic triphenylphosphine (PPh3) as coligands. The half-sandwich compounds were found to be stable in aqueous solution, and the Rh(III) derivatives exhibited promising antiproliferative and HDAC inhibitory activity compared to their chlorido precursor. The lipophilic Rh-PPh3 compound was effectively taken up into human cancer cells, where it caused α-tubulin hyperacetylation with low impact on the histone H3 acetylation level. Molecular docking studies revealed additional interactions on the surface of the protein due to the presence of the P-donor ligands. Coordination of a CoIII(cyclen) chaperone to the hydroxamic acid moiety yielded reduction-responsive heterobimetallic compounds in which the bioactivity of the hydroxamic acid moiety was effectively masked.

View source

Similar papers

Sep 2026

Design of L-borneol-containing biguanide derivatives and their half-sandwich Ru(II)-p-cymene complexes: DNA/HSA binding properties, antioxidant activity and antiproliferative effects in glioblastoma cells.

In this study, half-sandwich Ru(II)-p-cymene complexes containing L-borneol-based biguanide ligands were synthesized, characterized and evaluated for their biological properties. Lipophilicity (logP) and hydrolysis studies demonstrated that the biguanide moiety and its substituents significantly influence hydration beh...

Abdulmecit Gul, Hüsne Gülseren Kalay, Julide Nacaroğlu Ballı et al. · 0 citations
Oct 2026

Discovery of 4-Aminoquinazoline Derivatives as Potent PKMYT1 Inhibitors via Hydrogen Bond Donor-To-Acceptor Conversion for CCNE1-Amplified Cancers.

PKMYT1 is a critical regulator of the cell cycle and has emerged as a promising synthetic lethal target for CCNE1-amplified cancers. In this study, we report the design, synthesis, and biological evaluation of a novel series of 4-aminoquinazoline-based PKMYT1 inhibitors. A hydrogen bond donor-to-acceptor conversion str...

Hai-Xiang Qi, Rui Lu, Yi-Fei Zhu et al. · 0 citations
Open access Sep 2026

Computationally Guided Design of New Naphthalene-Oxazole-Hydrazone Derivatives as Potential HDAC Inhibitors: ADME Assessment, Molecular Docking, Molecular Dynamics, and MM/GBSA Analysis

Computational findings suggest that the designed naphthalene–oxazole–hydrazone derivatives emerged as the most promising candidate among the designed derivatives based on the computational analyses that warrant further synthesis and biological evaluation.

Noor Waleed · 0 citations
Sep 2026

Discovery of pyrimidine-based dual CDK2/TrkA inhibitors: Synthesis, antiproliferative activity, and mechanistic insights.

A series of newly synthesized pyrimidine analogues 12a-o was developed as dual CDK2/TrkA inhibitors. Synthesis of the target compounds was achieved via a condensation reaction of methyl trifluoroacetoacetate with thiourea, followed by alkylation with various benzyl chlorides. Subsequent chlorination with POCl3 and fina...

Aya M. Slly, Wafaa A. Ewes, Waleed A. Bayoumi et al. · 0 citations
Open access Sep 2026

Dual inhibitors of CDK2 and TRKA kinases: design, synthesis, antiproliferative activity and molecular modeling of novel pyrazolopyrimidine derivatives

Simultaneous inhibition of CDK2 and TRKA presents a promising therapeutic avenue for cancer treatment, capitalizing on the critical roles of CDK2 in cell cycle regulation and TRKA in tumor cell survival and progression. In continuation of our previous work on dual CDK2/TRKA inhibitors, two series of pyrazolo[1,5-a]pyri...

Mohamed H. Attia, Deena S. Lasheen, Nermin Samir et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.